Unicycive Therapeutics, Inc.UNCYNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
69.37%
↑ 69% above average
Average (26q)
41.16%
Historical baseline
Range
High:665.92%
Low:-63.96%
Volatility
1773.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 69.37% |
| Q2 2025 | -19.39% |
| Q1 2025 | -58.94% |
| Q4 2024 | 73.66% |
| Q3 2024 | -37.45% |
| Q2 2024 | -28.55% |
| Q1 2024 | 60.95% |
| Q4 2023 | 25.53% |
| Q3 2023 | 48.74% |
| Q2 2023 | -25.18% |
| Q1 2023 | -21.09% |
| Q4 2022 | -20.05% |
| Q3 2022 | 158.23% |
| Q2 2022 | -3.78% |
| Q1 2022 | 42.03% |
| Q4 2021 | -63.96% |
| Q3 2021 | 665.92% |
| Q2 2021 | 9.56% |
| Q1 2021 | 17.80% |
| Q4 2020 | 25.66% |
| Q3 2020 | 67.03% |
| Q2 2020 | 22.97% |
| Q1 2020 | -60.64% |
| Q4 2019 | 100.00% |
| Q3 2019 | 62.77% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |